TABLE 1.
Experimental interventions used in this study
| Animal | Initial inoculationa | Initial treatment (start/duration)b | Time of initial homologous rechallenge (wk after initial inoculation) | Time of second homologous rechallenge (wk after initial inoculation) | Time of heterologous rechallenge (wk after initial inoculation) | Time of CD8 depletionc (wk after initial inoculation) |
|---|---|---|---|---|---|---|
| Experimental animals | ||||||
| Rh 120 | E660 | PMPA (24 h/28 days) | 10 | 75 | 98 | 86 |
| Rh 300 | E660 | PMPA (24 h/28 days) | 10 | 75 | 98 | 86 |
| Rh 009 | E660 | PMPA (24 h/28 days) | 10 | 75 | 85 | 98 |
| Rh 092 | E660 | PMPA (72 h/63 days) | 65 | NA | 75 | 90 |
| Rh 155 | E660 | PMPA (72 h/28 days) | 65 | NA | 75 | 90 |
| Control animals | ||||||
| Rh 128 | E660 | None | NA | NA | NA | NA |
| Rh 058 | E660 | None | NA | NA | NA | NA |
| Rh 106 | E660 | None | NA | NA | NA | NA |
| Rh 294 | E660 | None | NA | NA | NA | NA |
| Rh 226 | E660 | None | NA | NA | NA | NA |
| Rh 169 | E660 | None | NA | NA | NA | NA |
| Rh 399 | 239 | None | NA | NA | NA | NA |
| Rh 405 | 239 | None | NA | NA | NA | NA |
a
E660, intravenous inoculation with 30 MID50 of SIVsmE660; 239, intravenous inoculation with 100 MID50 of SIVmac239.
b
PMPΔ, treatment with tenofovir (PMPΔ; 30 mg/kg, subcutaneously, once daily).
c
CD8 depletion, treatment with the anti-CD8 MAb cMT807, 10 mg/kg subcutaneously followed by 5 mg/kg, intravenously, 2 and 6 days later.